H.C. Wainwright Reiterates Buy Rating on Immix Biopharma, Inc. (IMMX)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $7.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).

The analyst commented: "Yesterday, Immix Biopharma announced that it is now dosing at dose expansion level of 450M NXC-201 CAR+T cells in the U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy; the first cohort at 150M CAR+T cells was already successfully completed. Advancement to the second dosing cohort of three patients at 450M CAR-T cells will dose one patient with NXC-201 every 28 days, subsequently enabling multiple patients to be dosed per month in NEXICART-2. We note that this trial builds upon the previously presented ex-U.S. data for NXC-201, in r/r AL amyloidosis. We reiterate our Buy rating and 12-month price target of $7."

For an analyst ratings summary and ratings history on Immix Biopharma, Inc. click here. For more ratings news on Immix Biopharma, Inc. click here.

Shares of Immix Biopharma, Inc. closed at $1.46 yesterday.

You May Also Be Interested In

• Rosenblatt Starts CoreWeave (CRWV) at Buy
• CVB Financial (CVBF) Declares $0.20 Quarterly Dividend; 3.6% Yield
• Zodiac Gold closes C$5.6M private placement one day late